BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22138178)

  • 1. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction.
    den Brok MH; Nierkens S; Wagenaars JA; Ruers TJ; Schrier CC; Rijke EO; Adema GJ
    Vaccine; 2012 Jan; 30(4):737-44. PubMed ID: 22138178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Frielink C; Toonen LW; Boerman OC; Figdor CG; Ruers TJ; Adema GJ
    Br J Cancer; 2006 Oct; 95(7):896-905. PubMed ID: 16953240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
    Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines.
    Castro-Díaz N; Salaun B; Perret R; Sierro S; Romero JF; Fernández JA; Rubio-Moraga A; Romero P
    Vaccine; 2012 Jan; 30(2):388-97. PubMed ID: 22079266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
    Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
    Front Immunol; 2018; 9():2874. PubMed ID: 30619259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
    Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
    Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
    Ren W; Strube R; Zhang X; Chen SY; Huang XF
    Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
    Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
    Fong CL; Mok CL; Hui KM
    Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
    den Brok MH; Sutmuller RP; van der Voort R; Bennink EJ; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2004 Jun; 64(11):4024-9. PubMed ID: 15173017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
    Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
    Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.